Kornimate/medical-research-clean huggingface dataset:
a banded one anastomosis gastric bypass with use shape-memory ring versus non-banded one anastomosis gastric bypass

Conditions: Obesity

Summary: background and study aims: currently, the gastric bypass is increasingly performed in the version of the mini gastric bypass (mgb). another name for the procedure: one anastomosis gastric bypass (oagb). insufficient weight loss after bariatric surgery or weight gain after surgery is a common big problem in weight loss surgery. the use of unregulated and uncontrolled bands and rings is not always effective according to previous studies. this study compares the loss of weight after the laparoscopic banded one anastomosis gastric bypass with the use of a shape-memory ring and standard laparoscopic one anastomosis gastric bypass. methods: adult participants (n=100) are randomly allocated to one of two groups: experimental surgical bariatric procedure in the first (a) group: patients (n=50) will undergo the laparoscopic banded one anastomosis gastric bypass with use of a shape-memory ring (mgb/oagb+smr group); active comparator surgical bariatric procedure in the second (b) group: patients (n=50) will undergo the laparoscopic one anastomosis gastric bypass (mgb/oagb group) without band: standard surgery. all patients are then followed up 12, 24, 36 months after surgery where record the changing body mass index.

this study compares the loss of weight after the laparoscopic banded one anastomosis gastric bypass with the use of a shape-memory ring and standard laparoscopic one anastomosis gastric bypass. inclusion criteria: * bmi from 30 to 50 kg / m2; * ages eligible for study: 18 years to 55 years outcome measures: change of body mass index \[ time frame: baseline, at 12, 24, 36 months after surgery \]

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of obesity; 2. bmi from 30 to 50 kg / m2. exclusion criteria: 1. insulin-dependent diabetes; 2. bmi less than 30 kg / m2 and more than 50 kg / m2.

Keywords: obesity bariatric surgery ring with shape memory one anastomosis gastric bypass
exercise intolerance and skeletal muscle bioenergetics in children with deep venous thrombosis

Conditions: Deep Vein Thrombosis; Pulmonary Embolism

Summary: this is a prospective cohort study of 30 patients who are 8-21 years of age with venous thromboembolism (vte)- either lower extremity deep venous thrombosis (dvt) or pulmonary embolism (pe).

participants will be in three groups- those with lower extremity dvt, those with pe, or those with both lower extremity dvt and pe. patients will have blood drawn for thrombin generation assay, thromboelastography assay, and thromboinflammatory panel in addition to standard of care labs for diagnosis of vte and management of anticoagulation. the patients will then fill out questionnaires on quality of life and level of exercise at their first outpatient visit 4 weeks after diagnosis. at approximately 3-6 months after diagnosis, patients will undergo two days of testing for the research study. all patients will have exercise testing using bicycle ergometry to measure global aerobic fitness. they will once again fill out questionnaires about their quality of life and level of physical activity. after a 24 hour rest period, dvt patients will undergo 31p-mr spectroscopy and non-invasive spin labeling mri to provide data on skeletal muscle bioenergetics (phosphocreatine metabolism), and lymphatic and venous flow respectively in the affected leg compared to the unaffected leg. this will allow each patient to be his or her own control. after these research procedures, patients will continue to receive standard of care treatment for their vte in the bleeding and thrombosis clinic.

Eligibility criteria:
inclusion criteria: * age 8- ≤ 21 years old and * lower extremity deep venous thrombosis or * lower extremity deep venous thrombosis and pulmonary embolism or * pulmonary embolism exclusion criteria: * contraindications to exercise, such as post-surgical patients with cast immobility or fractures * patients unable to follow instructions/commands at baseline due to developmental delay * patients with congenital heart disease and abnormal pulmonary circulation/perfusion * contraindications to undergoing magnetic resonance imaging
to assess the safety and efficacy of r932348 ophthalmic solutions in patients with keratoconjunctivitis sicca

Conditions: Keratoconjunctivitis Sicca

Summary: the purpose of this study is to determine whether 0.2% and 0.5% r348 ophthalmic solutions are safe and effective in the treatment of patients with keratoconjunctivitis sicca.


Eligibility criteria:
inclusion criteria: * a history of dry eye (based on the date of initial dry eye symptoms) * use of over-the-counter (otc) and/or prescription eye drops for dry eye symptoms * corneal fluorescein staining score of at least 2 in the inferior region exclusion criteria: * history of, or a concurrent clinically significant illness, medical condition (other than keratoconjunctivitis sicca or sjögren's syndrome), or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study. * use of ophthalmic cyclosporine within 45 days of visit 1. * use of any topical ophthalmic steroid within 2 weeks of visit 1. * have worn contact lenses or anticipate using contact lenses during the study. * have a condition or be in a situation that the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study. * have a history of alcohol or substance abuse that, in the judgment of the investigator, may impair or risk the subject's full participation in the study.
the effect of bruxism on temporomandibular disorders

Conditions: Bruxism; Temporomandibular Disorder

Summary: this case-control study consists of 120 participants aged between 18 and 65 years. case group included 60 patients with bruxism who presented to physical medicine and rehabilitation outpatient clinic between may 2021 and august 2021. control group included 60 healthy participant. patients who had temporomandibular region surgery, congenital teporomandibular joint pathologies, and previous temporomandibular region trauma were also excluded. assessments including age, gender, body mass index (bmi), education level, and symptom duration were recorded. patients was evaluated according to the diagnostic criteria for temporomandibular disorders: assessment instruments. patients was evaluated by diagnostic criteria for temporomandibular disorders: tmd pain screener, symptom questionnaire, clinical examination form from assessment instruments axis i. pain drawing, graded chronic pain (version 2), jaw functional limitation scale-8 (jfls-8), patient health questionnaire (phq-4) , oral behaviors checklist were applied within the scope of axis ii.

the aim of this study was to effect of bruxism on temporomandibular disorders (tmd) diagnosed by means of the research diagnostic criteria for temporomandibular disorders (rdc/tmd). this case-control study consists of 120 participants aged between 18 and 65 years. case group will be included 60 patients with bruxism who presented to physical medicine and rehabilitation outpatient clinic between may 2021 and august 2021. control group will be included 60 healthy participant. patients who had temporomandibular region surgery, congenital teporomandibular joint pathologies, and previous temporomandibular region trauma were also excluded. assessments including age, gender, body mass index (bmi), education level, and symptom duration will be recorded. patients will evaluated according to the diagnostic criteria for temporomandibular disorders: assessment instruments. patients was evaluated by diagnostic criteria for temporomandibular disorders: tmd pain screener, symptom questionnaire, clinical examination form from assessment instruments axis i. pain drawing, graded chronic pain (version 2), jaw functional limitation scale-8 (jfls-8), patient health questionnaire (phq-4) , oral behaviors checklist will applied within the scope of axis ii.

Eligibility criteria:
inclusion criteria: * sixty patients diagnosed with bruxism according to self-reported bruxism and examination. * sixty healthy volunteers exclusion criteria: * patients with temporomandibular region surgery * congenital teporomandibular joint pathologies * previous temporomandibular region trauma were excluded from the study.

Keywords: bruxism temporomandibular disorder
a study of prt811 in participants with advanced solid tumors, cns lymphoma and gliomas

Conditions: Advanced Solid Tumor; Recurrent Glioma

Summary: this is a phase 1 dose-escalation study of prt811, a protein arginine n-methyltransferase (prmt) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. the purpose of this study is to define a safe dose and schedule to be used in subsequent development of prt811.

this is a multicenter, open-label, dose-escalation, dose-expansion phase 1 study of prt811, a prmt5 inhibitor, in subjects with advanced cancers without any approved or available treatment options including solid tumors, cns lymphoma, and /or high-grade gliomas. the study will consist of 2 parts, a dose escalation part evaluating subjects with advanced solid tumors, cns lymphoma, and/or high-grade glioma and a cohort expansion part which will evaluate the safety and efficacy of prt811 in subjects with advanced solid tumors, and glioblastoma multiforme. for subjects, the study will include a screening phase, a treatment phase, and a post treatment follow-up phase. an end-of-study visit will be conducted within 30 days after the last dose of prt811.

Eligibility criteria:
inclusion criteria: * malignancies that are refractory to or intolerant of established therapies known to provide clinical benefit for the malignancy in question, or in the opinion of the investigator, not be a candidate for such therapies * subjects must have recovered from the effects of any prior investigational system therapies * for subjects with recurrent high-grade glioma or gbm, must have biopsy proven evidence (who grade iii or iv) and received external bean fractionated radiotherapy and at least 2 cycles of adjuvant temozolomide chemotherapy. mutant glioma must comply with biomarker defined enrollment criterias. * for biomarker-selected solid tumors: must meet enrollment criteria * eastern cooperative oncology group (ecog) performance score of 0 or 1 * adequate organ function (bone marrow, hepatic, renal, cardiovascular) * female subjects of childbearing potential must have a negative pregnancy test within 7 days of the start of treatment and must agree to use an effective method of contraception during the trial exclusion criteria: * untreated concurrent malignancies or malignancies that have been in complete remission for less than one year * treatment with strong inhibitors of cyp3a4 for which there are no therapeutic substitutions * inflammatory disorders of the gastrointestinal tract, or subjects with gi malabsorption * hiv positive; known active hepatitis b or c * known hypersensitivity to any of the components of prt811

Keywords: prmt5 prmt5 inhibitor
retrospective safety study to compare mortality in intensive care unite (icu) patients undergoing echocardiography with or without definity®

Conditions: Cardiovascular Disease

Summary: retrospective analysis to observe changes in short term mortality


Eligibility criteria:
inclusion criteria: * males and females * at least 18 years of age

Keywords: cad
young adult education on alcohol & health

Conditions: Sexual Behavior; Alcohol Drinking; Condomless Sex

Summary: the goal of this clinical trial is to test the effectiveness of our brief online program when compared to those who don't complete the program at all.

a total of 300 participants will complete this 6 month study. the study will include a background survey, 5 week monitoring period where participants either complete the brief online program with check-in surveys or check-in surveys only, and follow-up surveys 1, 3, and 6 months later.

Eligibility criteria:
inclusion criteria: * assessed as part of screening procedures exclusion criteria: * do not want to participate
supramaximal titrated inhibition of raas in dilated cardiomyopathy

Conditions: Dilated Cardiomyopathy

Summary: dilated cardiomyopathy (dcm) is a poorly understood cause of systolic heart failure and is the most common indication for heart transplantation worldwide. despite advances in medical and device therapy, the 5-year mortality of patients with dcm remains high. patients diagnosed of dilated cardiomyopathy with a nyha functional class of ii to iv and left ventricular ejection fraction(lvef) \<35% were selected for randomized controlled study of the efficacy and safety of high dose renin-angiotensin system (ras) inhibitor (benazepril or valsartan), in comparison with low dose ras inhibitor(benazepril or valsartan) and standard beta-adrenergic blocker therapy (metoprolol). the primary endpoint was all cause death or admission for heart failure. additional prespecified outcomes included all-cause death, cardiovascular death, all-cause admission, heart failure admission. secondary cardiovascular outcomes included the changes from baseline to the last available observation after treatment in nyha functional class, quality-of-life scores, lvef, lvedd, mitral regurgitation and wall-motion score index assessed by ecg. adverse events were reported during in-hospital observation and follow-ups.


Eligibility criteria:
inclusion criteria: * diagnosis of dilated cardiomyopathy * left ventricular ejection fraction \< 35% * nyha functional classes of ii-iv * symptomatic but not rapidly deteriorating 1 month before enrollment * signed informed consent exclusion criteria: * contradictions and intolerance of the studied drugs: * supine systolic arterial blood pressure \< 90 mmhg, * renal artery stenosis \>50%, * pregnancy or lactation, * impaired renal function (estimated glomerular filtration rate \< 60 ml/min/1.73m2, * impaired liver function (total bilirubin \>2 times upper limit of normal, * serum aspartate ast or alanine alt \>3 times the upper limit of normal), * hemoglobin less than 8 mg/dl, hyperkalaemia (serum potassium \>5.5mmol/l), * obstructive lung disease, * advanced atrioventricular block, * any co-morbidity with impact on survival, and * known intolerance to benazepril, valsartan and metoprolol succinate; * hf secondary to a known cause: * coronary artery disease based on coronary angiography (≥50% stenosis in ≥1 of the major coronary arteries) and/or a history of myocardial infarction or angina pectoris, * acute or subacute stage of myocarditis, * primary valve disease, * diabetes mellitus, * excessive use of alcohol or illicit drugs; * expected or performed cardiac resynchronization therapy and heart transplantation.

Keywords: dilated cardiomyopathy high dose acei/arb
mbct for people with parkinson's disease and caregivers

Conditions: Parkinson Disease; Anxiety; Depression

Summary: this study aims to explore the feasibility and effectiveness of mindfulness-based cognitive therapy (mbct) in reducing anxiety and/or depressive symptoms in people with parkinson's disease (pd) and caregivers of people with pd.

an adapted mbct intervention will be offered to people with parkinson's disease (pd) and mild-to-moderate depression and/or anxiety, as well as caregivers of people with pd. several 8-week long mbct groups will be held between september 2020 and may 2021, based on the adapted protocol. the mbct intervention will consist of 90-minute weekly groups focused on teaching mindfulness techniques and ways to recognize cognitive patterns that can increase anxiety and/or depression. participants will be recruited from the community, according to the eligibility criteria detailed below. for all participants, the pre- and post-mbct anxiety and/or depressive symptom severity and mindfulness levels (as measured with standardized, validated scales) will be compared, using a paired t-test. for caregivers, pre- and post-mbct caregiver burden scores will be compared as well.

Eligibility criteria:
inclusion criteria: * having a diagnosis of parkinson's disease (pd) or parkinsonism, established by a neurologist, or being a caregiver of a person with pd or parkinsonism * being able and willing to attend 8 weekly 90-minute online group sessions (5-6:30 pm pst) * mild-to-moderate anxiety: gad-7 score ≤ 16 * mild-to-moderate depression: phq-9 score ≤ 18 exclusion criteria: * severe anxiety: gad-7 score \> 16 * moderately severe-to-severe depression: phq-9 score \> 18 * cognitive impairment: montreal cognitive assessment (moca) score \< 24 * heavy alcohol or drug use * severe psychosis * active suicidal or homicidal ideation * for people with pd: severe motor fluctuations (less than 2 hours "on" time per day) * pattern of engagement with health care that indicates low likelihood of completing an 8-week intervention.

Keywords: parkinson's disease mindfulness-based intervention mindfulness-based cognitive therapy (mbct)
assessment of serum levels of vitamin d, vitamin b12 and folic acid among patients with lifelong premature ejaculation and non-responding to dapoxetine treatment.

Conditions: Vitamin D, Vitamin B12 and Folic Acid Among Patients With Premature Ejaculation

Summary: therefore, this study will aim to assess serum levels of vitamin d, vitamin b12 and folic acid among patients with lifelong pe and non-responding to dapoxetine treatment.

we will consider the patients with lpe non-responding to dapoxetine treatment when they used the optimum dose (30 and 60mg) dapoxetine for 4 separate times with no response. serum vitamin d, vitamin b12, and folic acid levels will be assessed in all subjects included in the study. venous blood samples will be drawn and kept into edta bottles in the morning between 8 and 10 a.m. after an overnight fast of about 10-14 hr.

Eligibility criteria:
inclusion criteria: * premature ejaculation * non-responding to dapoxetine treatment. exclusion criteria: * diabetes mellitus, * chronic prostatitis, * advanced renal or hepatic diseases * neurological diseases and * c.n.s. medications

Keywords: premature ejaculation
"serratus anterior plane block" versus "serratus posterior superior plane intercostal plane block" for patients undergoing breast surgery

Conditions: Pain, Postoperative; Breast Cancer; Anesthesia; Mastectomy

Summary: the serrato posterosuperior block (spsip) is a recently discovered technique that provides analgesia to the hemithorax, shoulders, neck and back. at an anatomical level, it has been seen that this technique allows the diffusion of local anesthetic starting from c7 proceeding dorsally up to t10 by sectioning the trapezius, latissimus dorsi, rhomboid and erector spinae muscles. the serratus anterior block (sapb) is a technique that allows local anesthetic to be injected between the serratus anterior muscle and the intercostal muscles (deep plane) or between the latissimus dorsi muscle and the serratus anterior muscle (superficial plane), also providing analgesia at of the chest wall. this study aims to compare the analgesic efficacy of spsipb and sapb in patients undergoing radical mastectomy for breast cancer


Eligibility criteria:
inclusion criteria: * adult patient ( \> 18 years) * informed consent * american society of anaesthesiologis phisical status i to iii * patients undergoing for mastectomy with sentinel lynphnode byopsy/axillary clearence exclusion criteria: * pregnant women * allergy to any drug present in the protocol
evaluation of quality of care - patient empowerment programme, ha

Conditions: Diabetes Mellitus; Hypertension

Summary: diabetes mellitus (dm) and hypertension (ht) are major causes of morbidity and among the top 10 causes of deaths in hong kong in 2008 (department of health 2009). the hospital authority (ha) has initiated service improvement through introducing the patient empowerment programme (pep) to improve the quality of care (qoc) for dm and ht patients. the evaluation on the qoc is an essential part of the programme in order to inform future policy. the family medicine unit (fmu) of the university of hong kong (hku) has been appointed by the ha to carry out the evaluation of the qoc of the programme. the action learning and audit spiral methodologies to measure whether the target standard of care intended by the pep programme is achieved. each pep participating clinic and non-government organization (ngo) will be invited to complete a structured evaluation questionnaire. the data of all patients who have enrolled into the pep for more than one year will be included in the evaluation on the process and outcomes of care. a hundred and thirty participants will be followed up by telephone to evaluate the effect of the programme in quality of life (qol), patient enablement, and global rating of change in health condition at baseline and 6 months after enrolment. data on the process of care will be retrieved from the ha medical records. main outcome measures: the primary outcomes are the proportion of participants who have received the planned process of care and achieved the target hba1c and blood pressure levels. data analysis: descriptive statistics on proportions meeting the qoc criteria will be calculated. the changes in clinical, service, and patient reported outcomes at 6 and 12 months will assessed by paired sample t-test. the audit cycle will be repeated annually over a period of 5 years. results: the qoc of the pep programme will be determined. areas of deficiency and possible areas for quality enhancement will be identified. conclusion: the results of this study will provide empirical evidence on whether the ha's pep programme can enhance qoc for patients with diabetes mellitus (dm) or hypertension (ht). the information will be used to guide service planning and policy decision making.


Eligibility criteria:
inclusion criteria: * eligible patients who are ambulatory, have stable mental and emotional conditions, and follow up at general outpatients clinics (gopc) and family medicine specialist clinics (fmsc) regularly will be recruited for the pep programme. exclusion criteria: * patients will be excluded if they have severe heart failure, end stage renal failure (esrf) or advanced eye diseases, are unable to understand or communicate in chinese language, or refuse to give consent.

Keywords: diabetes mellitus (dm) hypertension (ht) hong kong